Arrow Financial Corp Has $392,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)

Arrow Financial Corp reduced its stake in Pfizer Inc. (NYSE:PFE) by 18.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,543 shares of the biopharmaceutical company’s stock after selling 3,091 shares during the quarter. Arrow Financial Corp’s holdings in Pfizer were worth $392,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of PFE. China Universal Asset Management Co. Ltd. bought a new position in Pfizer during the 1st quarter worth $315,000. GSA Capital Partners LLP acquired a new stake in Pfizer in the 1st quarter worth about $439,000. Duality Advisers LP bought a new stake in Pfizer in the 1st quarter valued at about $1,009,000. Atomi Financial Group Inc. grew its position in shares of Pfizer by 103.4% during the 1st quarter. Atomi Financial Group Inc. now owns 37,422 shares of the biopharmaceutical company’s stock worth $1,038,000 after purchasing an additional 19,024 shares in the last quarter. Finally, Stonebrook Private Inc. acquired a new stake in shares of Pfizer in the first quarter valued at approximately $229,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Scott Gottlieb bought 1,000 shares of the business’s stock in a transaction on Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now owns 10,000 shares of the company’s stock, valued at $282,400. This represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and raised their price target for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Citigroup started coverage on shares of Pfizer in a research report on Friday, October 25th. They set a “neutral” rating and a $30.00 price objective for the company. Barclays increased their price objective on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Finally, Sanford C. Bernstein assumed coverage on shares of Pfizer in a report on Thursday, October 17th. They set a “market perform” rating and a $32.00 price target for the company. Eight research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and a consensus price target of $33.58.

Pfizer Stock Down 1.2 %

Shares of PFE opened at $26.72 on Friday. The stock has a market capitalization of $151.42 billion, a price-to-earnings ratio of 36.11, a PEG ratio of 0.87 and a beta of 0.67. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.60 and a current ratio of 1.00. The stock has a fifty day moving average of $28.89 and a 200-day moving average of $28.63.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same period last year, the firm posted ($0.17) earnings per share. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.29%. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.